Editas Medicine (EDIT) Price & Analysis

Compare

3,546 Followers

EDIT Stock Chart & Stats

$2.47

-$0.10(-7.24%)

At close: Jan 08 4:00 PM EST

$2.47

-$0.10(-7.24%)

Day’s Range― - ―

52-Week Range$0.91 - $4.54

Previous CloseN/A

Volume963.61K

Average Volume (3M)2.47M

Market Cap

$246.00M

Enterprise Value$225.69M

Total Cash (Recent Filing)$165.65M

Total Debt (Recent Filing)$19.65M

Price to Earnings (P/E)―

Beta2.23

Next Earnings

Feb 19, 2026

EPS Estimate

-0.23

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.28

Shares Outstanding97,618,660

10 Day Avg. Volume1,860,597

30 Day Avg. Volume2,474,043

Financial Highlights & Ratios

PEG Ratio-0.01

Price to Book (P/B)0.78

Price to Sales (P/S)3.24

P/FCF Ratio-0.48

Enterprise Value/Market Cap0.92

Enterprise Value/Revenue4.87

Enterprise Value/Gross Profit4.87

Enterprise Value/Ebitda-1.28

Forecast

1Y Price Target

$3.64

Price Target Upside47.37% Upside

Rating ConsensusHold

Number of Analyst Covering12

EPS Forecast (FY)-2.02

Revenue Forecast (FY)$22.31M

Bulls Say, Bears Say

Bulls Say

Gene Editing InnovationEditas has nominated EDIT-401, an in vivo gene editor, to be used in the treatment of atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia, showing promising preclinical data with ~90% reduction in LDL-C.

Preclinical SuccessEDIT-401 demonstrated a ~90% mean LDL-C reduction in animal models, showcasing its potential efficacy and safety with no concerning adverse events.

Strategic PositioningEditas' pivot to cardiovascular disease could better position the company as a takeout target given the recent acquisition deals in the cardiovascular disease space for gene editing companies.

Bears Say

Clinical Development ConcernsThe long road to initial clinical data remains a key holdup of the stock, which is why the HOLD rating is reiterated.

Competitive ChallengesSignificant spending may be needed to compete in the large hyperlipidemia addressable market, with Editas likely a few years behind in development compared to key competitors.

Safety And Efficacy UncertaintiesThe actual LNP used in the therapy has not yet been tested in clinical settings, leading to uncertainties about its effectiveness and safety.

Editas Medicine News

Editas Medicine price target lowered to $3.50 from $12 at Chardan

Chardan lowered the firm’s price target on Editas Medicine (EDIT) to $3.50 from $12 and keeps a Buy...

9d ago

EDIT

FDA appoints Richard Pazdur as Director of CDER

The U.S. Department of Health and Human Services and the U.S. Food and Drug Administration announced that Richard...

10d ago

AZN

BMY

Editas Medicine price target raised to $4.60 from $4 at Clear Street

Clear Street raised the firm’s price target on Editas Medicine (EDIT) to $4.60 from $4 and keeps a...

11d ago

EDIT

Editas Medicine reports Q3 EPS (28c), consensus (38c)

Reports Q3 revenue $7.54M, consensus $4.94M. “We are incredibly excited by the progress we made in the third...

11d ago

EDIT

FDA to speed up gene editing therapy approvals, Bloomberg reports

The FDA plans to introduce a faster approval process for custom gene-editing therapies, allowing combined trials for patients...

21d ago

CRSP

EDIT

Video: This stock is dragging down the in vivo gene editing therapy space

The Fly has brought its to-the-moment stock market reporting to YouTube! Listen and subscribe. Published first on TheFly...

25d ago

MGX

BEAM

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30...

25d ago

MGX

CRSP

Intellia Therapeutics price target lowered to $30 from $36 at BofA

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy...

25d ago

BEAM

CRBU

Editas Medicine management to meet with Cantor

Meeting to be held in Denver on October 27 and in San Francisco on October 28 hosted by...

29d ago

EDIT

Cautious Hold Rating on Editas Medicine Amid Promising Preclinical Results and Development Uncertainties

JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating today. Soumit...

10d ago

EDIT

Editas Medicine Reports Q3 2025 Progress and Financials

Editas Medicine Inc. ( ($EDIT) ) has released its Q3 earnings. Here is a breakdown of the information...

11d ago

EDIT

Editas Medicine Inc. (EDIT) Q3 Earnings Cheat Sheet

Editas Medicine Inc. (EDIT) is scheduled to report 3rd quarter earnings on 11/10/2025. Regarding Q3 estimates, Wall Street...

13d ago

EDIT

Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies

Editas Medicine Inc. (($EDIT)) announced an update on their ongoing clinical study. Study Overview: Editas Medicine Inc. is...

25d ago

EDIT

Editas Medicine Unveils Promising Preclinical Data on EDIT-401

Editas Medicine ( ($EDIT) ) has provided an update. On October 9, 2025, Editas Medicine presented in vivo...

1M ago

EDIT

EDIT FAQ

What was Editas Medicine Inc’s price range in the past 12 months?

Editas Medicine Inc lowest stock price was $0.91 and its highest was $4.54 in the past 12 months.

What is Editas Medicine Inc’s market cap?

Editas Medicine Inc’s market cap is $246.00M.

When is Editas Medicine Inc’s upcoming earnings report date?

Editas Medicine Inc’s upcoming earnings report date is Feb 19, 2026 which is in 90 days.

How were Editas Medicine Inc’s earnings last quarter?

Editas Medicine Inc released its earnings results on Nov 10, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.016.

Is Editas Medicine Inc overvalued?

According to Wall Street analysts Editas Medicine Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Editas Medicine Inc pay dividends?

Editas Medicine Inc does not currently pay dividends.

What is Editas Medicine Inc’s EPS estimate?

Editas Medicine Inc’s EPS estimate is -0.23.

How many shares outstanding does Editas Medicine Inc have?

Editas Medicine Inc has 97,618,660 shares outstanding.

What happened to Editas Medicine Inc’s price movement after its last earnings report?

Editas Medicine Inc reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went up 2.024%.

Which hedge fund is a major shareholder of Editas Medicine Inc?

Currently, no hedge funds are holding shares in EDIT

Editas Medicine Stock Smart Score

Neutral

Fundamentals

Return on Equity

-211.37%

Trailing 12-Months

Asset Growth

-38.41%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Editas Medicine Inc

Editas Medicine (EDIT) is a biotechnology company focused on developing transformative genomic medicines using its proprietary CRISPR gene-editing technology. The company operates primarily in the field of genetic medicine, targeting diseases caused by genetic mutations, including inherited retinal diseases and other serious conditions. Editas aims to leverage its innovative platform to create therapies that can correct the underlying genetic causes of diseases, with a pipeline that includes both in vivo and ex vivo applications of CRISPR technology.

Editas Medicine (EDIT) Earnings & Revenues

Historic Earnings Reports

EDIT Stock 12 Month Forecast

Average Price Target

$3.64

▲(47.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","3":"$3","6":"$6","1.5":"$1.5","4.5":"$4.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.5,3,4.5,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.08,3.227692307692308,3.3753846153846156,3.523076923076923,3.670769230769231,3.8184615384615386,3.966153846153846,4.113846153846154,4.2615384615384615,4.409230769230769,4.556923076923077,4.704615384615384,4.852307692307692,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.08,3.123076923076923,3.166153846153846,3.2092307692307696,3.2523076923076926,3.2953846153846156,3.3384615384615386,3.3815384615384616,3.4246153846153846,3.4676923076923076,3.510769230769231,3.553846153846154,3.596923076923077,{"y":3.64,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.08,2.92,2.7600000000000002,2.6,2.44,2.2800000000000002,2.12,1.96,1.8,1.6400000000000001,1.48,1.32,1.1600000000000001,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.55,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.08,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >